Postpartum Depression Screening (EPDS)

The Edinburgh Postnatal Depression Scale is a 10-item self-report questionnaire developed in 1987 by Cox, Holden, and Sagovsky specifically to identify women at risk for postnatal depression. It asks about mood, anxiety, difficulty coping, and thoughts of self-harm over the past 7 days. It is the most widely used and validated screening tool for perinatal depression worldwide, used by OBGYNs, midwives, and pediatricians.

Baby blues (also called postpartum blues) refer to mild, transient mood changes that affect up to 80% of new mothers within the first 2 weeks after birth — tearfulness, emotional sensitivity, irritability, anxiety, and mood swings. These typically resolve on their own within 2 weeks. Postpartum depression (PPD) is more persistent and more severe, lasting beyond 2 weeks, occurring in roughly 1 in 7 mothers. PPD includes depressed mood most of the day, loss of pleasure or interest, significant anxiety, difficulty bonding with baby, sleep disturbances beyond newborn demands, feelings of worthlessness, and in severe cases, thoughts of self-harm.

PPD can begin any time during pregnancy (prenatal depression) or within the first year after birth, though it most commonly appears within the first 4 weeks. It can begin subtly and worsen gradually. Without treatment, PPD can persist for months or years. With appropriate treatment — therapy, medication, or a combination — most women recover fully. Early identification and treatment lead to faster, more complete recovery.

Yes — several antidepressants are considered safe during breastfeeding. Sertraline (Zoloft) and paroxetine (Paxil) are the most studied and transfer minimally into breast milk. Your prescribing physician or psychiatrist can weigh the benefits and risks based on your specific situation. The risk of untreated PPD to mother-baby bonding often outweighs the minimal risk of low-level medication exposure through breast milk.

Yes. Paternal postnatal depression affects an estimated 8–10% of new fathers. Partners can experience symptoms similar to PPD — persistent sadness, irritability, withdrawal, problems sleeping, and difficulty engaging with the baby. Risk is higher when the mother is also experiencing PPD. The EPDS has also been validated for use in fathers and partners. Men are often less likely to seek help, so it's important to recognize the signs and encourage supportive conversations.

Treatment for PPD includes: (1) Psychotherapy — Cognitive Behavioral Therapy (CBT) and Interpersonal Therapy (IPT) are particularly effective for PPD; (2) Medication — SSRIs and SNRIs are commonly prescribed; brexanolone (Zulresso) is an IV medication FDA-approved specifically for severe PPD; (3) Support groups — Postpartum Support International (PSI) offers online and in-person peer support groups; (4) Lifestyle support — sleep, exercise, nutrition, reducing isolation, and building practical support systems. Most women need a combination of approaches. Talk to your healthcare provider to find the right plan.